K. Patel

发表

The economics of treating chronic hepatitis C patients with peginterferon α‐2a (40 kDa) plus ribavirin presenting with persistently normal aminotransferase *

J. Hornberger, S. Zeuzem, D. Prati, 2006, Journal of viral hepatitis.

Cost-Effectiveness of Combination Peginterferon α-2a and Ribavirin Compared With Interferon α-2b and Ribavirin in Patients With Chronic Hepatitis C

S S Lee, W. Klaskala, Jesse Green, 2004, American Journal of Gastroenterology.

A comparison of cost-effectiveness of peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (copegus) vs interferon alfa-2b plus ribavirin as first treatment of chronic hepatitus C (CHC)

Jesse Green, A. Alberti, S. Sullivan, 2003 .

Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C.

W. Klaskala, T. Hassanein, S. Sullivan, 2004, The American journal of gastroenterology.

Cost-effectiveness of peginterferon &agr;-2a compared with lamivudine treatment in patients with HBe-antigen-positive chronic hepatitis B in the United Kingdom

Julia E. Aledort, S. Sullivan, D. Veenstra, 2007, European journal of gastroenterology & hepatology.

Patient Acceptance of Self-Injected Enfuvirtide at 8 and 24 Weeks

S. Staszewski, M. Johnson, Jesse Green, 2003, HIV clinical trials.

Cost Effectiveness of Peginterferon α-2a Plus Ribavirin versus Interferon α-2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

Jesse Green, N. Wintfeld, A. Alberti, 2012, PharmacoEconomics.

Cost effectiveness of peginterferon alpha-2a plus ribavirin versus interferon alpha-2b plus ribavirin as initial therapy for treatment-naive chronic hepatitis C.

Jesse Green, N. Wintfeld, A. Alberti, 2004, PharmacoEconomics.

HBeAg-negative chronic hepatitis B: cost-effectiveness of peginterferon alfa-2a compared to lamivudine in Taiwan.

S. Sullivan, M. Lai, D. Veenstra, 2008, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Cost‐effectiveness of peginterferon alfa‐2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan

S. Sullivan, D. Veenstra, Ting Chang, 2007, Journal of gastroenterology and hepatology.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life

Sanjeev Arora, Jesse Green, N. Wintfeld, 2006, Journal of gastroenterology and hepatology.

Jesse Green, N. Wintfeld, C. Cohen, 2004, Journal of acquired immune deficiency syndromes.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.

Sanjeev Arora, Jesse Green, N. Wintfeld, 2006, Journal of gastroenterology and hepatology.

Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.

John Hornberger, Francesca J Torriani, J. Hornberger, 2006, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

PGI5 COST-EFFECTIVENESS OF TREATING ADULTS WITH CHRONIC HEPATITIS C (CHC) AND PERSISTENTLY NORMAL ALANINE AMINOTRANSFERASE (PNALT) WITH PEGINTERFERON ALFA-2A (40KD) (PEGASYS) PLUS RIBAVIRIN (COPEGUS)

J. Hornberger, Jesse Green, D. Prati, 2004 .